Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Sep 20, 2026, 6:50 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 31 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Conditions
Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer
Interventions
Arm A: Vitamin D3 Group, Placebo
Dietary Supplement
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older · Female only
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
2
States / cities
Chicago, Illinois • Evanston, Illinois
Conditions
BRCA1 Mutation, BRCA2 Mutation, Atypia Suspicious for Malignancy
Interventions
MAKO 7
Device
Lead sponsor
nVision Medical
Industry
Eligibility
18 Years and older · Female only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
3
States / cities
San Francisco, California • Walnut Creek, California • Charlottesville, Virginia
Conditions
Endometrial Cancer, Endometrial Cancer Precursors, Ovarian Cancer, Complex Atypical Endometrial Hyperplasia
Interventions
Not listed
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years to 99 Years · Female only
Enrollment
1,700 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2027
U.S. locations
1
States / cities
Birmingham, Alabama
Conditions
Stage I Endometrial Carcinoma, Stage II Endometrial Carcinoma, Stage III Endometrial Carcinoma, Stage IV Endometrial Carcinoma
Interventions
lymph node mapping, sentinel lymph node biopsy, isosulfan blue, indocyanine green solution, therapeutic conventional surgery, lymphadenectomy
Procedure · Drug
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
Female only
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Cleveland, Ohio
Conditions
Oophorectomy, Hysterectomy
Interventions
Bilateral salpingo-oophorectomy, Ovarian conservation
Procedure
Lead sponsor
University of California, San Francisco
Other
Eligibility
40 Years to 55 Years · Female only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2009
U.S. locations
2
States / cities
Birmingham, Alabama • San Francisco, California
Conditions
BRCA1 Gene Mutation, BRCA2 Gene Mutation
Interventions
Not listed
Lead sponsor
University of California, San Francisco
Other
Eligibility
35 Years to 50 Years · Female only
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
1
States / cities
San Francisco, California
Conditions
Fallopian Tube Cancer, Ovarian Cancer, Ovarian Neoplasms, Ovary Cancer, Fallopian Tube Neoplasms, Fallopian Tube Adenocarcinoma, High Grade Serous Carcinoma, Peritoneal Carcinoma, Peritoneal Neoplasms, Adnexal Mass, Ovarian Diseases
Interventions
Hysteroscopic cell sampling of the fallopian tube
Device
Lead sponsor
Boston Scientific Corporation
Industry
Eligibility
18 Years and older · Female only
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
10
States / cities
San Diego, California • San Francisco, California • Jacksonville, Florida + 7 more
Conditions
Surgical Procedure, Unspecified
Interventions
Computerized decision aid with 1 type of value clarification
Behavioral
Lead sponsor
University of California, San Francisco
Other
Eligibility
40 Years to 55 Years · Female only
Enrollment
63 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2014
U.S. locations
1
States / cities
San Francisco, California
Conditions
Endometrial Cancer Stage I, Sentinel Lymph Node, Surgery
Interventions
TH BSO with SNB Note: If participants (≤45yo), Grade 1 endometrial adenocarcinoma with myometrial invasion <50%, wish to retain their ovaries a BSO may be omitted, TH BSO without retroperitoneal node dissection Note: If participants (≤45yo), Grade 1 endometrial adenocarcinoma with myometrial invasion <50%, wish to retain their ovaries a BSO may be omitted
Procedure
Lead sponsor
Queensland Centre for Gynaecological Cancer
Government
Eligibility
18 Years and older · Female only
Enrollment
760 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2031
U.S. locations
1
States / cities
Houston, Texas
Conditions
Prolapse Pelvic, Hysterectomy
Interventions
Uterosacral suspension, Hysterectomy by vNOTES approach
Procedure
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years and older · Female only
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Houston, Texas
Conditions
BRCA1 Mutation, BRCA2 Mutation
Interventions
Experimental Arm, SOC Arm
Behavioral
Lead sponsor
Duke University
Other
Eligibility
19 Years to 50 Years · Female only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
2
States / cities
Chapel Hill, North Carolina • Durham, North Carolina
Conditions
Ovarian Carcinoma
Interventions
Bilateral Salpingectomy, Bilateral Salpingectomy with Oophorectomy, Biospecimen Collection, Magnetic Resonance Imaging, Quality-of-Life Assessment, Questionnaire Administration, Transvaginal Ultrasound, Ultrasound Imaging
Procedure · Other
Lead sponsor
NRG Oncology
Other
Eligibility
35 Years to 50 Years · Female only
Enrollment
1,956 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2047
U.S. locations
564
States / cities
Birmingham, Alabama • Anchorage, Alaska • Goodyear, Arizona + 372 more
Conditions
Breast Cancer
Interventions
Ribociclib
Drug
Lead sponsor
Georgetown University
Other
Eligibility
18 Years and older · Female only
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
3
States / cities
Washington D.C., District of Columbia • Boston, Massachusetts
Conditions
FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma, FIGO Grade 2 Endometrial Endometrioid Adenocarcinoma
Interventions
Bilateral Salpingectomy with Oophorectomy, Biospecimen Collection, Hysterectomy, Laboratory Biomarker Analysis, Lymph Node Mapping, Sentinel Lymph Node Biopsy
Procedure · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Female only
Enrollment
518 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2026
U.S. locations
1
States / cities
Houston, Texas
Conditions
Cervical Cancer, Ovarian Cancer, Uterine Cancer
Interventions
LigaSure vessel sealing system
Device
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
21 Years and older · Female only
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2017
U.S. locations
1
States / cities
New York, New York
Terminated Phase 2 Interventional Accepts healthy volunteers Results available

PSMA PET and MRI in Gynecological Cancers

NCT03302156
Conditions
Gynecologic Cancer
Interventions
PSMA-based 18F-DCFPyL PET tracer
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years to 99 Years · Female only
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2020
U.S. locations
1
States / cities
Madison, Wisconsin
Conditions
Breast Carcinoma, Fallopian Tube Carcinoma, Ovarian Neoplasm, Primary Peritoneal Carcinoma
Interventions
Evaluation of Cancer Risk Factors, Quality-of-Life Assessment, Questionnaire Administration, Study of High Risk Factors
Procedure · Other
Lead sponsor
Gynecologic Oncology Group
Network
Eligibility
30 Years and older · Female only
Enrollment
1,916 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2020
U.S. locations
141
States / cities
Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 106 more
Conditions
Ovarian Carcinoma
Interventions
Denosumab, Salpingo-Oophorectomy
Biological · Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Female only
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
4
States / cities
Boston, Massachusetts • New York, New York • Houston, Texas
Conditions
Ovarian Cancer
Interventions
flutamide
Drug
Lead sponsor
University of Arizona
Other
Eligibility
18 Years to 83 Years · Female only
Enrollment
127 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2014
U.S. locations
1
States / cities
Tucson, Arizona
Completed No phase listed Observational

A Case Report of NMDAR Encephalopathy

NCT06915103
Conditions
Anti-NMDA Receptor Encephalitis, Mature Teratoma, Paraneoplastic Syndromes
Interventions
Magnetic Resonance Imaging (MRI), Salpingo-oophorectomy
Diagnostic Test · Procedure
Lead sponsor
Mayo Clinic
Other
Eligibility
34 Years to 34 Years · Female only
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
1
States / cities
Jacksonville, Florida
Conditions
Ovarian Cancer, Fallopian Tube Cancer
Interventions
RIsk-Reducing Salpingectomy (RRS), Risk-Reducing Oophorectomy-RRO, Risk-Reducing Salpingo-Oophorectomy-RRSO
Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
9
States / cities
Boston, Massachusetts • Rochester, Minnesota • St Louis, Missouri + 4 more
Conditions
Cholecystectomy, Benign Hysterectomy, Salingo-oophorectomy
Interventions
Cannula and Blunt Obturator
Device
Lead sponsor
Minimally Invasive Devices, Inc.
Industry
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
1
States / cities
Miami, Florida
Conditions
Deleterious BARD1 Gene Mutation, Deleterious BRCA1 Gene Mutation, Deleterious BRCA2 Gene Mutation, Deleterious BRIP1 Gene Mutation, Deleterious EPCAM Gene Mutation, Deleterious MLH1 Gene Mutation, Deleterious MSH2 Gene Mutation, Deleterious MSH6 Gene Mutation, Deleterious PALB2 Gene Mutation, Deleterious PMS2 Gene Mutation, Deleterious RAD51C Gene Mutation, Deleterious RAD51D Gene Mutation, Hereditary Breast and Ovarian Cancer Syndrome, Premenopausal
Interventions
Laboratory Biomarker Analysis, Oophorectomy, Quality-of-Life Assessment, Salpingectomy, Salpingo-Oophorectomy
Other · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
30 Years to 50 Years · Female only
Enrollment
374 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2041
U.S. locations
9
States / cities
Chicago, Illinois • Boston, Massachusetts • Rochester, Minnesota + 5 more
Conditions
Breast Cancer, Ovarian Cancer
Interventions
Not listed
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
19 Years to 100 Years · Female only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
1
States / cities
Bethesda, Maryland